Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis.
OpenAlex 토픽 ·
Peptidase Inhibition and Analysis
Advanced Proteomics Techniques and Applications
Connective tissue disorders research
[BACKGROUND] The incidence of lung diseases has been increasing in recent years, especially lung cancer and interstitial lung disease.
- 95% CI 0.90-1.00
- 연구 설계 Meta-analysis
APA
Delong Huang, Qiaoli Zhao, et al. (2026). Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis.. Pulmonology, 32(1), 2638024. https://doi.org/10.1080/25310429.2026.2638024
MLA
Delong Huang, et al.. "Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis.." Pulmonology, vol. 32, no. 1, 2026, pp. 2638024.
PMID
41810601
Abstract
[BACKGROUND] The incidence of lung diseases has been increasing in recent years, especially lung cancer and interstitial lung disease. However, the diagnosis of lung diseases such as lung cancer and ILD still has some limitations. Therefore, finding an appropriate imaging agent and technique is of great clinical value for the diagnostic evaluation of lung diseases.
[METHOD] A thorough search of all relevant literature up to 20 June 2024 was undertaken. Studies evaluating lung lesions with FAPI PET were screened and patient diagnostic data were extracted. Risk of bias was checked by the QUADAS-2. Meta-analysis was performed in STATA17.0. Subgroups were analysed for the effectiveness of FAPI PET/CT in the diagnostic assessment of various lung diseases.
[RESULT] 19 studies were finally sieved. Meta-analysis showed that the sensitivity of FAPI PET/CT for the detection of lung tumours was 0.99 (95% CI: 0.90-1.00), with a specificity of 0.82 (95% CI: 0.72-0.89). The sensitivity of FAPI PET/CT for the assessment of non-neoplastic lesions was 0.93 (95% CI: 0.72-0.99) and the specificity was 0.96 (95% CI: 0.79-0.99). Subgroup analysis showed that FAPI PET/CT had a sensitivity of 0.93 (95% CI: 0.83-0.97) in lung tumour staging ( = 397). In addition, the sensitivity and specificity of FAPI PET/CT were 0.80 (95% CI: 0.70-0.89) and 0.90 (95% CI: 0.84-0.96) for pneumonia, and 1.00 for assessing idiopathic pulmonary fibrosis.
[CONCLUSION] Our results show that FAPI PET/CT has an excellent diagnostic performance for lung tumours and non-tumour lesions.: Currently CT is unable to accurately determine the activity of lung diseases such as IPF and hence may lead to delays in the diagnosis and treatment of some lung diseases. We aimed to find evidence-based medical evidence suitable for FAPI PET in lung diseases, especially non-oncological diseases, by performing a meta-analysis of FAPI PET in assessing lung diseases.
[METHOD] A thorough search of all relevant literature up to 20 June 2024 was undertaken. Studies evaluating lung lesions with FAPI PET were screened and patient diagnostic data were extracted. Risk of bias was checked by the QUADAS-2. Meta-analysis was performed in STATA17.0. Subgroups were analysed for the effectiveness of FAPI PET/CT in the diagnostic assessment of various lung diseases.
[RESULT] 19 studies were finally sieved. Meta-analysis showed that the sensitivity of FAPI PET/CT for the detection of lung tumours was 0.99 (95% CI: 0.90-1.00), with a specificity of 0.82 (95% CI: 0.72-0.89). The sensitivity of FAPI PET/CT for the assessment of non-neoplastic lesions was 0.93 (95% CI: 0.72-0.99) and the specificity was 0.96 (95% CI: 0.79-0.99). Subgroup analysis showed that FAPI PET/CT had a sensitivity of 0.93 (95% CI: 0.83-0.97) in lung tumour staging ( = 397). In addition, the sensitivity and specificity of FAPI PET/CT were 0.80 (95% CI: 0.70-0.89) and 0.90 (95% CI: 0.84-0.96) for pneumonia, and 1.00 for assessing idiopathic pulmonary fibrosis.
[CONCLUSION] Our results show that FAPI PET/CT has an excellent diagnostic performance for lung tumours and non-tumour lesions.: Currently CT is unable to accurately determine the activity of lung diseases such as IPF and hence may lead to delays in the diagnosis and treatment of some lung diseases. We aimed to find evidence-based medical evidence suitable for FAPI PET in lung diseases, especially non-oncological diseases, by performing a meta-analysis of FAPI PET in assessing lung diseases.
MeSH Terms
Humans; Lung Neoplasms; Sensitivity and Specificity; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Lung Diseases; Serine Endopeptidases; Endopeptidases
같은 제1저자의 인용 많은 논문 (5)
- Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.
- Chemical tools for discriminating single nucleotide variants: from design principles to clinical applications.
- Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.
- Exempting axillary staging surgery in breast cancer using multimodal ultrasound imaging and radiomics of sentinel lymph nodes.
- MSI1 Accelerates Prostate Cancer Cell Proliferation, Migration and Glycolysis by Promoting ABHD2 Transcription.